Biotech News
Related news
EXELExelixis2026-08-05 20:05 EST
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
EXELExelixis2026-07-22 20:30 EST
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
RVMDRevolution Medicines2026-06-24 23:31 EST
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
LYELLyell Immunopharma2026-06-01 12:00 EST
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
GERNGeron2026-06-01 12:00 EST
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST
Teva to Present at the Goldman Sachs Global Healthcare Conference
LYELLyell Immunopharma2026-06-25 12:00 EST
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
REPLReplimune Group2026-05-31 12:00 EST
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
ZNTLZentalis2026-07-17 20:15 EST
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
CMPXCompass Therapeutics2026-07-17 14:42 EST
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Exelixis
Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is...
Recent company news
EXELExelixis2026-08-05 20:05 EST
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
EXELExelixis2026-07-22 20:30 EST
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
EXELExelixis2026-06-22 12:00 EST
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
EXELExelixis2026-05-30 14:00 EST
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
EXELExelixis2026-05-27 20:05 EST
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Stock data
- Close
- 52.20 USD
- Market cap
- 12.2B USD
- Exchange
- NASDAQ
- Sector
- Small Molecule Drugs
- Location
- United States